Thursday, October 29, 2026
News For Internet Marketers
USA Today's October 21 guide sends GLP-1 patients to state pharmacy license lookups, PCAB or CCE accreditation checks, and FDA's compounding actions list. An analysis of what telehealth sellers can disclose about the dispensing pharmacy to build trust and limit disputes.
The Mississippi Board of Pharmacy's October 2026 newsletter says a certificate of analysis alone does not satisfy the state's joint peptide statement, that human-use disclaimers do not prevent enforcement, and that out-of-state telehealth prescribers need a Mississippi license.
DEA's final rule creating a special registration for telemedicine has been under OMB review since August 25, 2026, with a November target and no public text, while the temporary flexibilities that let practitioners prescribe Schedule II through V drugs to never-seen patients expire at the end of December 31.
Eli Lilly's six retatrutide lawsuits came with a call for card companies and processors to cut off sellers, and a CBS News investigation then found more than 80 businesses promoting the unapproved drug under LegitScript's seal, raising the bar for licensed telehealth and compounding merchants in underwriting.
Telehealth brands that bill consults and pharmacy fulfillment on separate MIDs can reduce statement confusion and chargebacks when checkout copy, refunds, and descriptors stay aligned. FDA GLP-1 telehealth pressure makes clean money flows part of processor survival too.
FDA's September 18, 2026 warning letter to Empower Pharmacy ties high-volume compounded GLP-1 combinations to telehealth-style menus that preselect significant-difference language under section 503A.
